Claims
- 1. An isolated antibody that specifically binds a protein having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:8 or an epitope extending from residue Q635 to residue P649 or from residue S220 to residue R239 of SEQ ID NO:1 or from residue H227 to residue R246 of SEQ ID NO:8.
- 2. A monoclonal antibody having the specificity of the antibody of claim 1.
- 3. The antibody of claim 1 wherein the antibody is identified with the protein having the amino acid sequence of SEQ ID NO:1 or an epitope extending from residue Q635 to residue P649 or from residue S220 to residue R239 of SEQ ID NO:1 by screening a plurality of intact immunoglobulin molecules, chimeric antibodies, polyclonal antibodies, recombinant antibodies, humanized antibodies, single chain antibodies, Fab fragments, F(ab′)2 fragments, or Fv fragments.
- 4. A method for using an antibody to detect differential expression of a protein in a sample, the method comprising:
a) combining the antibody of claim 1 with a sample under conditions which allow the formation of antibody:protein complexes; and b) detecting complex formation, wherein complex formation indicates differential expression of the protein in the sample.
- 5. The method of claim 4 wherein the sample is from prostate, pancreas or lung.
- 6. The method of claim 4 wherein complex formation is compared with at least one standard and is used to stage prostate cancer.
- 7. A composition comprising an antibody of claim 1 and a labeling moiety.
- 8. A kit comprising the composition of claim 1.
- 9. An array element comprising the antibody of claim 1.
- 10. A substrate upon which the antibody of claim 1 is immobilized.
- 11. A composition comprising the antibody of claim 1 and a pharmaceutical agent.
- 12. The composition of claim 11 wherein the composition is formulated to function in the prostate.
- 13. The composition of claim 11 wherein the pharmaceutical agent is a cytotoxic compound.
- 14. A method for using a composition to assess efficacy of a small drug molecule, the method comprising:
a) treating a sample containing the protein having the amino acid sequence of SEQ ID NO:1 with a molecule; b) contacting the protein in the sample with the composition of claim 7 under conditions for complex formation; and c) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates efficacy of the molecule.
- 15. A method for using a composition to assess toxicity of a compound, the method comprising:
a) treating a sample containing the protein having the amino acid sequence of SEQ ID NO:1 with a compound; b) contacting the protein in the sample with the composition of claim 7 under conditions for complex formation; and c) comparing the amount of complex formation in the treated sample with the amount of complex formation in an untreated sample, wherein a difference in complex formation indicates toxicity of the compound.
- 16. A method for treating prostate cancer comprising administering to a subject in need of therapeutic intervention the antibody of claim 1.
- 17. A method for treating prostate cancer comprising administering to a subject in need of therapeutic intervention the antibody of claim 2.
- 18. A method for treating prostate cancer comprising administering to a subject in need of therapeutic intervention the composition of claim 11.
- 19. A method for delivering an antibody to a subject in need of therapeutic intervention, wherein the antibody is formulated injection.
- 20. A method for delivering a pharmaceutical agent to the prostate comprising administering the composition of claim 11 to a subject in need of therapeutic intervention, wherein the composition specifically binds the protein having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:8 thereby delivering the pharmaceutical agent.
- 21. The antibody of claim 1 wherein the antibody is identified with the protein having the amino acid sequence of SEQ ID NO:8 or an epitope from residue H227 to residue R246 of SEQ ID NO:8 by screening a plurality of intact immunoglobulin molecules, chimeric antibodies, polyclonal antibodies, recombinant antibodies, humanized antibodies, single chain antibodies, Fab fragments, F(ab′)2 fragments, or Fv fragments.
Parent Case Info
[0001] This application is a continuation-in-part of co-pending U.S. Ser. No. 09/454,060 filed Dec. 2, 1999; which is a divisional of U.S. Pat. No. 6,080,548 filed Feb. 23, 1999; which is a divisional of U.S. Pat. No. 5,932,423 filed Nov. 19, 1997; which is a continuation-in-part of U.S. Pat. No. 5,798,246, entitled “Novel Cyclic Nucleotide Phosphodiesterases”, filed Mar. 25, 1996.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09255748 |
Feb 1999 |
US |
Child |
09454060 |
Dec 1999 |
US |
Parent |
08974565 |
Nov 1997 |
US |
Child |
09255748 |
Feb 1999 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09454060 |
Dec 1999 |
US |
Child |
10272970 |
Oct 2002 |
US |
Parent |
08624663 |
Mar 1996 |
US |
Child |
08974565 |
Nov 1997 |
US |